Laquinimod
Laquinimod (LAQ) is an orally administered immunomodulatory small molecule in advanced clinical development for multiple sclerosis. It has demonstrated efficacy in both in vivo experimental autoimmune encephalomyelitis models and in vitro studies targeting immune cell modulation.
Product Specifications
CAS Number
248281-84-7
Product Name Alternative
Chronic progressive, Apoptosis, carboxamide, ABR 215062, ABR215062, ABR-215062, Inhibitor, LAQ, Laquinimod, NFkB, neurodegeneration, neurodegenerative disease, Orally, Nuclear factor-κB, Nuclear factor-kappaB, NF-κB, NFκB, NF-kB, multiple sclerosis, inhibit, inflammation, immunomodulator, relapsing remitting
Field of Research
Cell Biology, Pharmacology & Drug Discovery, Signal Transduction
Purity
98.16% (May vary between batches)
Solubility
10% DMSO+90% Corn Oil:0.5 mg/mL (1.4 mM) ; Ethanol:1 mg/mL (2.8 mM) ; H2O:< 1 mg/mL (insoluble or slightly soluble) ; DMSO:8 mg/mL (22.42 mM)
Smiles
CCN (C (=O) c1c (O) n (C) c2cccc (Cl) c2c1=O) c1ccccc1
Molecular Formula
C19H17ClN2O3
Molecular Weight
356.8
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
036227-PE 200 µL
GPR151, CT (GPR151, PGR7, Probable G-protein coupled receptor 151, G-protein coupled receptor PGR7, GPCR-2037) (PE) discontinued
Sign In for Pricing
View Details